InterMune (ITMN -1.2%) slips a bit this morning after saying late yesterday that 2013 revenue...
InterMune (ITMN -1.2%) slips a bit this morning after saying late yesterday that 2013 revenue from sales of Esbriet will depend largely on the timing of its launch efforts in several European countries. The drug is designed for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease and is the only approved treatment worldwide.
Check out Seeking Alpha’s new Earnings Center »
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs